156 related articles for article (PubMed ID: 19819883)
41. Substantially altered expression pattern of cannabinoid receptor 2 and activated endocannabinoid system in patients with severe heart failure.
Weis F; Beiras-Fernandez A; Sodian R; Kaczmarek I; Reichart B; Beiras A; Schelling G; Kreth S
J Mol Cell Cardiol; 2010 Jun; 48(6):1187-93. PubMed ID: 19931541
[TBL] [Abstract][Full Text] [Related]
42. Endocannabinoids activate transient receptor potential vanilloid 1 receptors to reduce hyperdopaminergia-related hyperactivity: therapeutic implications.
Tzavara ET; Li DL; Moutsimilli L; Bisogno T; Di Marzo V; Phebus LA; Nomikos GG; Giros B
Biol Psychiatry; 2006 Mar; 59(6):508-15. PubMed ID: 16199010
[TBL] [Abstract][Full Text] [Related]
43. Endocannabinoid release from midbrain dopamine neurons: a potential substrate for cannabinoid receptor antagonist treatment of addiction.
Lupica CR; Riegel AC
Neuropharmacology; 2005 Jun; 48(8):1105-16. PubMed ID: 15878779
[TBL] [Abstract][Full Text] [Related]
44. Endocannabinoids and their role in fatty liver disease.
Mallat A; Lotersztajn S
Dig Dis; 2010; 28(1):261-6. PubMed ID: 20460921
[TBL] [Abstract][Full Text] [Related]
45. The role of the pancreatic endocannabinoid system in glucose metabolism.
Bermúdez-Silva FJ; Suárez Pérez J; Nadal A; Rodríguez de Fonseca F
Best Pract Res Clin Endocrinol Metab; 2009 Feb; 23(1):87-102. PubMed ID: 19285263
[TBL] [Abstract][Full Text] [Related]
46. Detailed characterization of the endocannabinoid system in human macrophages and foam cells, and anti-inflammatory role of type-2 cannabinoid receptor.
Chiurchiù V; Lanuti M; Catanzaro G; Fezza F; Rapino C; Maccarrone M
Atherosclerosis; 2014 Mar; 233(1):55-63. PubMed ID: 24529123
[TBL] [Abstract][Full Text] [Related]
47. Pleiotropic effects of the CB2 cannabinoid receptor activation on human monocyte migration: implications for atherosclerosis and inflammatory diseases.
Pacher P; Ungvári Z
Am J Physiol Heart Circ Physiol; 2008 Mar; 294(3):H1133-4. PubMed ID: 18203843
[No Abstract] [Full Text] [Related]
48. 2-Arachidonylglycerol acting on CB1 cannabinoid receptors mediates delayed cardioprotection induced by nitric oxide in rat isolated hearts.
Wagner JA; Abesser M; Harvey-White J; Ertl G
J Cardiovasc Pharmacol; 2006 May; 47(5):650-5. PubMed ID: 16775503
[TBL] [Abstract][Full Text] [Related]
49. CB1 and CB2 cannabinoid receptors differentially regulate the production of reactive oxygen species by macrophages.
Han KH; Lim S; Ryu J; Lee CW; Kim Y; Kang JH; Kang SS; Ahn YK; Park CS; Kim JJ
Cardiovasc Res; 2009 Dec; 84(3):378-86. PubMed ID: 19596672
[TBL] [Abstract][Full Text] [Related]
50. The hope and fear of rimonabant.
Rumsfeld JS; Nallamothu BK
JAMA; 2008 Apr; 299(13):1601-2. PubMed ID: 18387935
[No Abstract] [Full Text] [Related]
51. Rimonabant and progression of atherosclerosis in obese persons.
Dora JM; Scheffel RS
JAMA; 2008 Jul; 300(3):280; author reply 280-1. PubMed ID: 18632538
[No Abstract] [Full Text] [Related]
52. Endocannabinoid regulation of spinal nociceptive processing in a model of neuropathic pain.
Sagar DR; Jhaveri MD; Richardson D; Gray RA; de Lago E; Fernández-Ruiz J; Barrett DA; Kendall DA; Chapman V
Eur J Neurosci; 2010 Apr; 31(8):1414-22. PubMed ID: 20384778
[TBL] [Abstract][Full Text] [Related]
53. Alcohol inhibits spontaneous activity of basolateral amygdala projection neurons in the rat: involvement of the endocannabinoid system.
Perra S; Pillolla G; Luchicchi A; Pistis M
Alcohol Clin Exp Res; 2008 Mar; 32(3):443-9. PubMed ID: 18215217
[TBL] [Abstract][Full Text] [Related]
54. CB1 cannabinoid receptor antagonism: a new strategy for the treatment of liver fibrosis.
Teixeira-Clerc F; Julien B; Grenard P; Tran Van Nhieu J; Deveaux V; Li L; Serriere-Lanneau V; Ledent C; Mallat A; Lotersztajn S
Nat Med; 2006 Jun; 12(6):671-6. PubMed ID: 16715087
[TBL] [Abstract][Full Text] [Related]
55. Endocannabinoid control of food intake and energy balance.
Di Marzo V; Matias I
Nat Neurosci; 2005 May; 8(5):585-9. PubMed ID: 15856067
[TBL] [Abstract][Full Text] [Related]
56. Role of the basolateral nucleus of the amygdala in endocannabinoid-mediated stress-induced analgesia.
Connell K; Bolton N; Olsen D; Piomelli D; Hohmann AG
Neurosci Lett; 2006 Apr; 397(3):180-4. PubMed ID: 16378681
[TBL] [Abstract][Full Text] [Related]
57. [A role for the endocannabinoid system in hepatic steatosis].
Valenzuela C; Castillo V; Ronco AM; Aguirre C; Hirsch S; Llanos M
Rev Med Chil; 2014 Mar; 142(3):353-60. PubMed ID: 25052273
[TBL] [Abstract][Full Text] [Related]
58. Weeding out new drugs.
Ewan S
Drug Discov Today; 2005 Oct; 10(20):1336-7. PubMed ID: 16253865
[No Abstract] [Full Text] [Related]
59. Endocannabinoid system and cardio-metabolic risk.
Loh KY; Kew ST
Med J Malaysia; 2008 Oct; 63(4):348-50; quiz 351. PubMed ID: 19385504
[TBL] [Abstract][Full Text] [Related]
60. Central side-effects of therapies based on CB1 cannabinoid receptor agonists and antagonists: focus on anxiety and depression.
Moreira FA; Grieb M; Lutz B
Best Pract Res Clin Endocrinol Metab; 2009 Feb; 23(1):133-44. PubMed ID: 19285266
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
